ERAS-801: a selective brain-penetrant EGFR inhibitor with improved activity against EGFR extracellular domain-mutant glioblastoma

被引：0
|
作者：
Nathanson, D. [1 ]
Cadet, D. [2 ]
Okobi, Q. [2 ]
Urner, L. [3 ]
Jung, M. [3 ]
Cloughesy, T. [4 ]
机构：
[1] Univ Calif Los Angeles, Mol & Mol Pharmacol, Los Angeles, CA USA
[2] Univ Calif Los Angeles, Mol & Med Pharmacol, Los Angeles, CA USA
[3] Univ Calif Los Angeles, Chem, Los Angeles, CA USA
[4] Univ Calif Los Angeles, Neurol, Los Angeles, CA USA
来源：
EUROPEAN JOURNAL OF CANCER | 2024年 / 211卷
关键词：
D O I：
10.1016/j.ejca.2024.114657
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PB122
引用
收藏
页码：S55 / S56
页数：2
相关论文
共 19 条
  • [11] POTENT, SELECTIVE, AND BRAIN PENETRANT INHIBITORS OF EXTRACELLULAR DOMAIN EGFR ONCOGENIC MUTANTS EXPRESSED IN GBM DEMONSTRATE EFFICACY IN AN INTRACRANIAL PATIENT DERIVED XENOGRAFT MODEL
    O'Connor, Matthew
    Lucas, Matt
    Romashko, Darlene
    Rasmussen, Sara
    Fiorenza, Raffaele
    Lin, Tai-An
    Waters, Nigel
    Trainor, George
    Flohr, Alexander
    Ottaviani, Giorgio
    Roberts, Christopher
    Buck, Elizabeth
    Nicolaides, Theodore
    Raleigh, David
    Ozawa, Tomoko
    Arista, Luca
    NEURO-ONCOLOGY, 2020, 22 : 100 - 100
  • [12] ORIC-114, a highly selective, brain penetrant EGFR and HER2 inhibitor, demonstrates best-in-class properties against Exon 20 insertions and other atypical EGFR mutations
    Junttila, M.
    Repellin, C. E.
    Warne, R.
    Long, J. E.
    Sambucetti, L.
    Ashley, P.
    Andreatta, G.
    Baik, J.
    Salaniwal, S.
    Colas, C.
    Romero, A.
    Soroceanu, L.
    Patel, R.
    Maneval, E. Chow
    Multani, P. S.
    Daemen, A.
    Friedman, L.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S28 - S28
  • [13] Preclinical pharmacokinetic and pharmacological properties of ASP8273, a mutant-selective irreversible EGFR inhibitor, and its potential activity against brain metastases in NSCLC
    Fushiki, H.
    Kaneko, N.
    Yamanaka, Y.
    Fujita, Y.
    Noda, A.
    Umeda, N.
    Sakagami, H.
    EUROPEAN JOURNAL OF CANCER, 2016, 69 : S41 - S41
  • [14] Identification of STX-241, a CNS-penetrant and mutant-selective EGFR inhibitor with activity on osimertinib-resistant C797x mutations
    Pagliarini, Raymond A.
    Milgram, Benjamin C.
    Borrelli, Deanna R.
    O'Hearn, Erin
    Huff, Michael R.
    Ladd, Brendon
    Brooijmans, Natasja
    Wang, Weixue
    Kuzmic, Petr
    Guzman-Perez, Angel
    Stuart, Darrin D.
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [15] TTI-2341: A NOVEL, ORALLY BIOAVAILABLE, BRAIN-PENETRANT, COVALENT EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITOR FOR TREATMENT OF GLIOBLASTOMA MULTIFORME (GBM) AND BRAIN METASTASES OF NON-SMALL CELL LUNG CANCER (NSCLC)
    Wang, Zezhou
    Dove, Peter
    Rosa, David
    Marshall, Andrew
    Catalano, Tina
    Bossen, Bolette
    Choi, Jaehyun
    Wang, Chunlei
    Wong, Mark
    Winston, Jeff
    Slassi, Malik
    Petrova, Penka S.
    Uger, Robert A.
    NEURO-ONCOLOGY, 2017, 19 : 61 - 61
  • [16] TAS-121, A Selective Mutant EGFR Inhibitor, Shows Activity Against Tumors Expressing Various EGFR Mutations Including T790M and Uncommon Mutations G719X
    Ito, Kimihiro
    Nishio, Makoto
    Kato, Masanori
    Murakami, Haruyasu
    Aoyagi, Yoshimi
    Ohe, Yuichiro
    Okayama, Takashige
    Hashimoto, Akihiro
    Ohsawa, Hirokazu
    Tanaka, Gotaro
    Nonoshita, Katsumasa
    Ito, Satoru
    Matsuo, Kenichi
    Miyadera, Kazutaka
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (05) : 920 - 928
  • [17] A dual and selective small molecule inhibitor of EGFR and PI3 kinase shows promising preclinical activity against KRAS and BRAF mutant colorectal tumors
    Maust, Joel D.
    Ziemke, Elizabeth K.
    Frankowski-McGregor, Christy L.
    Ku, Jun Beom
    Mumby, Rachel
    Hardiman, Karin M.
    Whitehead, Christopher E.
    Sebolt-Leopold, Judith S.
    CANCER RESEARCH, 2017, 77
  • [18] NUV-520 (NVL-520) is a brain-penetrant and highly selective ROS1 inhibitor with antitumor activity against the G2032R solvent front mutation.
    Pelish, Henry E.
    Tangpeerachaikul, Anupong
    Kohl, Nancy E.
    Porter, James R.
    Shair, Matthew D.
    Horan, Joshua C.
    CANCER RESEARCH, 2021, 81 (13)
  • [19] NUV-655 (NVL-655) is a selective, brain-penetrant ALK inhibitor with antitumor activity against the lorlatinib-resistant G1202R/L1196M compound mutation.
    Pelish, Henry E.
    Tangpeerachaikul, Anupong
    Kohl, Nancy E.
    Porter, James R.
    Shair, Matthew D.
    Horan, Joshua C.
    CANCER RESEARCH, 2021, 81 (13)
12